Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Sonja Zweegman, Hélène Caillon, Denis Caillot, Hervé Avet-Loiseau, Michel Delforge, Thomas Dejoie, Thierry Facon, Cécile Sonntag, Jean Fontan, Mohamad Mohty, Kon-Siong Jie, Lionel Karlin, Frédérique Kuhnowski, Jérôme Lambert, Xavier Leleu, Margaret Macro, Frédérique Orsini-Piocelle, Murielle Roussel, Jean Marc Schiano de Colella, Niels WCJ van de Donk, Soraya Wuillème, Annemiek Broijl, Cyrille Touzeau, Mourad Tiab, Jean-Pierre Marolleau, Nathalie Meuleman, Marie-Christiane Vekemans, Matthijs Westerman, Saskia K Klein, Mark-David Levin, Fritz Offner, Martine Escoffre-Barbe, Jean-Richard Eveillard, Réda Garidi, Winnie Hua, Jianping Wang, Alba Tuozzo, Carla de Boer, Melissa Rowe, Veronique Vanquickelberghe, Robin Carson, Jessica Vermeulen, Jill Corre, Pieter Sonneveld

Open source

DOI
10.1016/s1470-2045(24)00282-1
Published
2024-08
Container
The Lancet Oncology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-24-00282-1,
  title = {Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial},
  author = {Philippe Moreau and Cyrille Hulin and Aurore Perrot and Bertrand Arnulf and Karim Belhadj and Lotfi Benboubker and Sonja Zweegman and Hélène Caillon and Denis Caillot and Hervé Avet-Loiseau and Michel Delforge and Thomas Dejoie and Thierry Facon and Cécile Sonntag and Jean Fontan and Mohamad Mohty and Kon-Siong Jie and Lionel Karlin and Frédérique Kuhnowski and Jérôme Lambert and Xavier Leleu and Margaret Macro and Frédérique Orsini-Piocelle and Murielle Roussel and Jean Marc Schiano de Colella and Niels WCJ van de Donk and Soraya Wuillème and Annemiek Broijl and Cyrille Touzeau and Mourad Tiab and Jean-Pierre Marolleau and Nathalie Meuleman and Marie-Christiane Vekemans and Matthijs Westerman and Saskia K Klein and Mark-David Levin and Fritz Offner and Martine Escoffre-Barbe and Jean-Richard Eveillard and Réda Garidi and Winnie Hua and Jianping Wang and Alba Tuozzo and Carla de Boer and Melissa Rowe and Veronique Vanquickelberghe and Robin Carson and Jessica Vermeulen and Jill Corre and Pieter Sonneveld},
  year = {2024},
  journal = {The Lancet Oncology},
  doi = {10.1016/s1470-2045(24)00282-1},
  url = {https://doi.org/10.1016/s1470-2045(24)00282-1}
}

RIS

TY  - JOUR
TI  - Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
AU  - Philippe Moreau
AU  - Cyrille Hulin
AU  - Aurore Perrot
AU  - Bertrand Arnulf
AU  - Karim Belhadj
AU  - Lotfi Benboubker
AU  - Sonja Zweegman
AU  - Hélène Caillon
AU  - Denis Caillot
AU  - Hervé Avet-Loiseau
AU  - Michel Delforge
AU  - Thomas Dejoie
AU  - Thierry Facon
AU  - Cécile Sonntag
AU  - Jean Fontan
AU  - Mohamad Mohty
AU  - Kon-Siong Jie
AU  - Lionel Karlin
AU  - Frédérique Kuhnowski
AU  - Jérôme Lambert
AU  - Xavier Leleu
AU  - Margaret Macro
AU  - Frédérique Orsini-Piocelle
AU  - Murielle Roussel
AU  - Jean Marc Schiano de Colella
AU  - Niels WCJ van de Donk
AU  - Soraya Wuillème
AU  - Annemiek Broijl
AU  - Cyrille Touzeau
AU  - Mourad Tiab
AU  - Jean-Pierre Marolleau
AU  - Nathalie Meuleman
AU  - Marie-Christiane Vekemans
AU  - Matthijs Westerman
AU  - Saskia K Klein
AU  - Mark-David Levin
AU  - Fritz Offner
AU  - Martine Escoffre-Barbe
AU  - Jean-Richard Eveillard
AU  - Réda Garidi
AU  - Winnie Hua
AU  - Jianping Wang
AU  - Alba Tuozzo
AU  - Carla de Boer
AU  - Melissa Rowe
AU  - Veronique Vanquickelberghe
AU  - Robin Carson
AU  - Jessica Vermeulen
AU  - Jill Corre
AU  - Pieter Sonneveld
PY  - 2024
JO  - The Lancet Oncology
DO  - 10.1016/s1470-2045(24)00282-1
UR  - https://doi.org/10.1016/s1470-2045(24)00282-1
ER  -

APA

Moreau, P., Hulin, C., Perrot, A., Arnulf, B., Belhadj, K., Benboubker, L., Zweegman, S., Caillon, H., Caillot, D., Avet-Loiseau, H., Delforge, M., Dejoie, T., Facon, T., Sonntag, C., Fontan, J., Mohty, M., Jie, K., Karlin, L., Kuhnowski, F., Lambert, J., Leleu, X., Macro, M., Orsini-Piocelle, F., Roussel, M., Colella, J. M. S. D., Donk, N. W. V. D., Wuillème, S., Broijl, A., Touzeau, C., Tiab, M., Marolleau, J., Meuleman, N., Vekemans, M., Westerman, M., Klein, S. K., Levin, M., Offner, F., Escoffre-Barbe, M., Eveillard, J., Garidi, R., Hua, W., Wang, J., Tuozzo, A., Boer, C. D., Rowe, M., Vanquickelberghe, V., Carson, R., Vermeulen, J., Corre, J., & Sonneveld, P. (2024). Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(24)00282-1

Source records